BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ragonnet R, Trauer JM, McBryde ES, Houben RM, Denholm JT, Handel A, Sumner T. Is IPT more effective in high-burden settings? Modelling the effect of tuberculosis incidence on IPT impact. Int J Tuberc Lung Dis 2017;21:60-6. [PMID: 28157466 DOI: 10.5588/ijtld.16.0297] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Padmapriyadarsini C, Sekar L, Reddy D, Chitra A, Poornagangadevi N, Selvaraj M, Bhavani PK, Mothi SN, Nandagopal K, Vennila S, Tamizhselvan M, Maheshmanisha J, Agarwal U, Rewari BB, Swaminathan S. Effectiveness of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected adults in programme setting. Indian J Med Res 2020;152:648-55. [PMID: 34145105 DOI: 10.4103/ijmr.IJMR_1582_18] [Reference Citation Analysis]
2 Kendall EA, Azman AS, Maartens G, Boulle A, Wilkinson RJ, Dowdy DW, Rangaka MX. Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting. AIDS 2019;33:525-36. [PMID: 30325773 DOI: 10.1097/QAD.0000000000002053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Kirwan DE, Gilman RH. A false economy: we cannot afford to be complacent when it comes to tuberculosis control. Lancet Public Health 2018;3:e105-6. [PMID: 29426598 DOI: 10.1016/S2468-2667(18)30019-7] [Reference Citation Analysis]
4 Wangari IM, Trauer J, Stone L. Modelling heterogeneity in host susceptibility to tuberculosis and its effect on public health interventions. PLoS One 2018;13:e0206603. [PMID: 30427891 DOI: 10.1371/journal.pone.0206603] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
5 Trauer JM, Kawai A, Coussens AK, Datta M, Williams BM, McBryde ES, Ragonnet R. Timing of Mycobacterium tuberculosis exposure explains variation in BCG effectiveness: a systematic review and meta-analysis. Thorax 2021:thoraxjnl-2020-216794. [PMID: 33893231 DOI: 10.1136/thoraxjnl-2020-216794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Mugomeri E, Olivier D, van den Heever WMJ. Tracking the rate of initiation and retention on isoniazid preventive therapy in a high human immunodeficiency virus and tuberculosis burden setting of Lesotho. S Afr J Infect Dis 2019;34:10. [PMID: 34485448 DOI: 10.4102/sajid.v34i1.10] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Sumner T, White RG. The predicted impact of tuberculosis preventive therapy: the importance of disease progression assumptions. BMC Infect Dis 2020;20:880. [PMID: 33228580 DOI: 10.1186/s12879-020-05592-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Ragonnet R, Williams BM, Largen A, Nasa J, Jack T, Langinlur MK, Ko E, Rahevar K, Islam T, Denholm JT, Marais BJ, Marks GB, McBryde ES, Trauer JM. Estimating the long-term effects of mass screening for latent and active tuberculosis in the Marshall Islands. Int J Epidemiol 2022:dyac045. [PMID: 35323964 DOI: 10.1093/ije/dyac045] [Reference Citation Analysis]
9 Doan TN, Varleva T, Zamfirova M, Tyufekchieva M, Keshelava A, Hristov K, Yaneva A, Gadzheva B, Zhang S, Irbe S, Ragonnet R, McBryde ES, Trauer JM. Strategic investment in tuberculosis control in the Republic of Bulgaria. Epidemiol Infect 2019;147:e304. [PMID: 31736454 DOI: 10.1017/S0950268819001857] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Kerschberger B, Schomaker M, Telnov A, Vambe D, Kisyeri N, Sikhondze W, Pasipamire L, Ngwenya SM, Rusch B, Ciglenecki I, Boulle A. Decreased risk of HIV-associated TB during antiretroviral therapy expansion in rural Eswatini from 2009 to 2016: a cohort and population-based analysis. Trop Med Int Health 2019;24:1114-27. [PMID: 31310029 DOI: 10.1111/tmi.13290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Mathiasen VD, Eiset AH, Andersen PH, Wejse C, Lillebaek T. Epidemiology of tuberculous lymphadenitis in Denmark: A nationwide register-based study. PLoS One 2019;14:e0221232. [PMID: 31415659 DOI: 10.1371/journal.pone.0221232] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
12 Briffoteaux G, Gobert M, Ragonnet R, Gmys J, Mezmaz M, Melab N, Tuyttens D. Parallel surrogate-assisted optimization: Batched Bayesian Neural Network-assisted GA versus q-EGO. Swarm and Evolutionary Computation 2020;57:100717. [DOI: 10.1016/j.swevo.2020.100717] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Abubakar I, Chakaya J, Maeurer M, Zumla A. Towards optimal treatment for latent Mycobacterium tuberculosis infection. Lancet Respir Med 2019;7:195-7. [PMID: 30823969 DOI: 10.1016/S2213-2600(19)30036-0] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Denholm JT, Silva DS, Burhan E, Chaisson RE. Tuberculosis Elimination in the Asia-Pacific Region and the WHO Ethics Guidance. Trop Med Infect Dis 2018;3:E115. [PMID: 30384409 DOI: 10.3390/tropicalmed3040115] [Reference Citation Analysis]
15 Parvaresh L, Bag SK, Cho JG, Heron N, Assareh H, Norton S, Corbett S, Marais BJ. Monitoring tuberculosis contact tracing outcomes in Western Sydney, Australia. BMJ Open Respir Res 2018;5:e000341. [PMID: 30397487 DOI: 10.1136/bmjresp-2018-000341] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]